verified SJR 11,205 · Q1 • database Scopus / SJR & Web of Science indexed

United States · Lippincott Williams and Wilk...

workspace_premium Q1 — Medicine (miscellaneous) visibility_off Single blind Peer Review lock_open Open Access Unclaimed

Journal of Clinical Oncology

The Journal of Clinical Oncology serves its readers as the single most credible, authoritative resource for disseminating significant clinical oncology research. In print and in electronic format, JCO strives to publish the highest quality articles dedicated to clinical research....

ISSN: 0732-183X

Editorial: Lippincott Williams and Wilkins

Category: Medicine (miscellaneous)

Indexation: verifiedScopus / SJR verifiedWeb of Science

Unclaimed profile — some fields may be incomplete.

open_in_new Visitar Portal de la Editorial menu_book Guía para Autores (Guidelines)

schedule Datos CoP · solo campos en BD

SJR Impact Factor trending_up

11,205 Q1

H-index 646

Tasa de Aceptación pie_chart

13% Alta selectividad

Fuente Acceptance_Rate

Tiempo a publicación hourglass_top

NPD

Campo Sin dato

Coste de Publicación (APC) payments

3.166 € Open Access

Ruta Non-OA NPD

Metrics

Campos Scimago / CoP — sin series inventadas

Scopus / SJR Web of Science

SJR Impact

11,205

H-index

646

Docs (year)

622

Docs 3y

1877

Total refs

17957

Cites 3y

26575

Citable 3y

1306

Cites/Doc 2y

13.85

Ref/Doc

28.87

Immediate OA

3166 €

Embargoed OA

NPD

Non OA / Submission

- €

shield Researcher voice

Name good journals. Call out predatory ones.

Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.

Fair & fast peer review Clear APC / no surprise fees Suspected predatory Fake impact claims

rate_review Write an honest review

Researcher reviews

sentiment_dissatisfied No reviews yet — be the first to share an honest experience.

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID * * Only to validate authenticity — identity is not shown publicly.

Best articles by citations

Cantuzumab Mertansine, a Maytansinoid Immunoconjugate Directed to the CanAg Antigen: A Phase I, Pharmacokinetic, and Biologic Correlative Study

VAMP and Low-Dose, Involved-Field Radiation for Children and Adolescents With Favorable, Early-Stage Hodgkin's Disease: Results of a Prospective Clinical Trial

Dose-response relationship of complementary radiotherapy following four cycles of combination chemotherapy in intermediate-stage Hodgkin's disease.

Dose intensity of MOPP chemotherapy and survival in Hodgkin's disease.

Dose Intensity of Chemotherapy in Patients With Relapsed Hodgkin's Lymphoma

Donor Lymphocyte Infusions Modulate Relapse Risk in Mixed Chimeras and Induce Durable Salvage in Relapsed Patients After T-Cell-Depleted Allogeneic Transplantation for Hodgkin's Lymphoma

Does histology influence outcome in childhood Hodgkin's disease? Results from the United Kingdom Children's Cancer Study Group.

Contemporarily Treated Patients With Hodgkin Lymphoma Have Childbearing Potential in Line With Matched Comparators

Combined-Modality Therapy Versus Radiotherapy Alone for Treatment of Early-Stage Hodgkin's Disease: Cure Balanced Against Complications

Combined modality treatment with low-dose radiation and MOPP chemotherapy for children with Hodgkin's disease.

Clinical stages I and II Hodgkin's disease: a specifically tailored therapy according to prognostic factors.

Classical Hodgkin's Disease and Follicular Lymphoma Originating From the Same Germinal Center B Cell

SHOW MORE ARTICLES

Characteristics and Outcomes of Breast Cancer in Women With and Without a History of Radiation for Hodgkin's Lymphoma: A Multi-Institutional, Matched Cohort Study

A phase I safety and pharmacokinetic (PK) study of navitoclax (N) in combination with docetaxel (D) in patients (pts) with solid tumors.

Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report.

Brentuximab Vedotin Combined With Donor Lymphocyte Infusions for Early Relapse of Hodgkin Lymphoma After Allogeneic Stem-Cell Transplantation Induces Tumor-Specific Immunity and Sustained Clinical Remission

Breast Cancer Screening in Women Previously Treated for Hodgkin's Disease: A Prospective Cohort Study

Autologous bone marrow transplantation for pediatric Hodgkin's disease: a case-matched comparison with adult patients by the European Bone Marrow Transplant Group Lymphoma Registry.

Assessment of Tumor Size Reduction Improves Outcome Prediction of Positron Emission Tomography/Computed Tomography After Chemotherapy in Advanced-Stage Hodgkin Lymphoma

Assessment of the Stanford V Regimen and Consolidative Radiotherapy for Bulky and Advanced Hodgkin's Disease: Eastern Cooperative Oncology Group Pilot Study E1492

Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle experience.

Allogeneic marrow transplantation in the treatment of MOPP-resistant Hodgkin's disease.

ABVD/MOPP and low-dose involved-field radiotherapy in pediatric Hodgkin's disease: the Stanford experience.

ABVD (8 cycles) versus BEACOPP (4 escalated cycles => 4 baseline) in stage III-IV high-risk Hodgkin lymphoma (HL): First results of EORTC 20012 Intergroup randomized phase III clinical trial.

FAQS

In Country of Papers you can find SJR impact factor and other metrics to help you decide on a Journal.